G9071 Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i or stage iia-iib; or t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
Billable / valid for submission HCPCS Release 2026Q3
Short description: Onc dx brst stg1-2b hr,nopro
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i or stage iia-iib; or t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) | yes |
Related codes in G90
- G9001 Coordinated care fee, initial rate
- G9002 Coordinated care fee, maintenance rate
- G9003 Coordinated care fee, risk adjusted high, initial
- G9004 Coordinated care fee, risk adjusted low, initial
- G9005 Coordinated care fee, risk adjusted maintenance
- G9006 Coordinated care fee, home monitoring
- G9007 Coordinated care fee, scheduled team conference
- G9008 Coordinated care fee, physician coordinated care oversight services
- G9009 Coordinated care fee, risk adjusted maintenance, level 3
- G9010 Coordinated care fee, risk adjusted maintenance, level 4
- G9011 Coordinated care fee, risk adjusted maintenance, level 5
- G9012 Other specified case management service not elsewhere classified
- G9013 Esrd demo basic bundle level i
- G9014 Esrd demo expanded bundle including venous access and related services
- G9016 Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
- G9050 Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)
- G9051 Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a medicare-approved demonstration project)
- G9052 Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
- G9053 Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
- G9054 Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies (for use in a medicare-approved demonstration project)